(Q36475488)

English

A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). (English)

1 reference

Europe PubMed Central

14 August 2017

0 references

multicenter clinical trial

0 references

0 references

placebo-controlled trial

1 reference

based on heuristic

inferred from title

object named as

Xiaoying Zhou

7

0 references

Alan A Montgomery

object named as

Alan Montgomery

12

0 references

object named as

Robin Spiller

13

0 references

Peter J Whorwell

object named as

Peter Whorwell

9

0 references

author name string

Ching Lam

1

1 reference

Europe PubMed Central

14 August 2017

Wei Tan

2

1 reference

Europe PubMed Central

14 August 2017

Matthew Leighton

3

1 reference

Europe PubMed Central

14 August 2017

Margaret Hastings

4

1 reference

Europe PubMed Central

14 August 2017

Melanie Lingaya

5

1 reference

Europe PubMed Central

14 August 2017

Yirga Falcone

6

1 reference

Europe PubMed Central

14 August 2017

Luting Xu

8

1 reference

Europe PubMed Central

14 August 2017

Andrew F Walls

10

1 reference

Europe PubMed Central

14 August 2017

Abed Zaitoun

11

1 reference

Europe PubMed Central

14 August 2017

language of work or name

0 references

publication date

12 March 2015

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

65

1 reference

Europe PubMed Central

14 August 2017

1

1 reference

Europe PubMed Central

14 August 2017

91-99

1 reference

Europe PubMed Central

14 August 2017

A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

Intestinal barrier function in health and gastrointestinal disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

Exacerbation of bloody diarrhea as a side effect of mesalamine treatment of active ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

Postinfectious irritable bowel syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

Functional bowel disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

Irritable bowel syndrome in general practice: prevalence, characteristics, and referral

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

Stool form scale as a useful guide to intestinal transit time

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

The hospital anxiety and depression scale

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

30 September 2017

Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

28 June 2018

Clinical economics review: irritable bowel syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

28 June 2018

Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

21 September 2018

Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

21 September 2018

Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

21 September 2018

Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

21 September 2018

The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

21 September 2018

Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

21 September 2018

Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

21 September 2018

Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

21 September 2018

Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

21 September 2018

The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

21 September 2018

Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

21 September 2018

Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

21 October 2018

Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4717357

21 October 2018

Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25765462

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diarrhea as a side effect of mesalamine treatment for inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25765462

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/GUTJNL-2015-309122

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36475488&oldid=1583828832"